ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis
- 1 April 2015
- journal article
- research article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 351 (1-2), 174-178
- https://doi.org/10.1016/j.jns.2015.02.019
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialThe Lancet Neurology, 2014
- Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritisBrain, 2011
- Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trialArthritis & Rheumatism, 2011
- Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trialArthritis & Rheumatism, 2011
- A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trialsBrain, 2010
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisThe New England Journal of Medicine, 2008
- Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatmentJournal of Neuroimmunology, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- A serial MRI study following optic nerve mean area in acute optic neuritisBrain, 2004
- B‐lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluidAnnals of Neurology, 2004